Live symbol workspace

XLV market intelligence

Chart, AI analysis, key levels, technical analysis, sentiment, and market news are grouped so the next action is always visible.

Current $146.81

Trend Flat

Sentiment Neutral

{# Only render the live technical grid when the AI analysis carries real, non-placeholder data. Sentinel payloads (data_status error/collecting, current_price 0) are handled by the Asset Intelligence Dossier below, which degrades to a calm branded empty state instead of "0%" widgets. #}

Detailed Market Analysis

Key Levels

Support

$139.47

Resistance

$154.15

Volume & Momentum

Volume

Weak

0.8x avg

Momentum

0%

Weak

Technical Analysis

HOLD

Entry $146.81

Stop $139.47

Target $154.15

RSI: 50 | Current: $146.81

Market Sentiment

50

Neutral

Stock Metrics

Daily Vol

0%

VIX Est

20

Weekly

0%

Asset Intelligence Dossier

Over the last 30 days, AI sentiment for XLV skewed bearish (2 of 4 scored calls).

Provider track record

Not enough scored provider calls yet for this asset.

Confidence trend

34%

▼ 6.0 pts vs previous week

Avg confidence across 10 calls in the last 7 days

What sources say

Bearish 2 articles

3 Healthcare Stocks with Open Questions

3 Healthcare Stocks We Steer Clear Of

Neutral 2 articles

Stocks Rise Pre-Bell as Investors Assess Renewed Middle East Tensions, Await Jobs Report

2 Healthcare Stocks Worth Your Attention and 1 We Ignore

Insider Trading

Refreshing insider trades from FinViz…

Technical Signals

Refreshing technical signals from FinViz…

XLV News Intelligence (7 articles)

AI-curated news influencing XLV price, sentiment, and trend

Explore All XLV News with AI Analysis

Stocks

1 month, 4 weeks ago

Pfizer and French partner to seek approval for Lyme disease vaccine after late-stage trial

Pharmaceutical giant Pfizer and French partner Valneva on Monday said they planned to seek regulatory approval for a Lyme disease …

Impact on XLV: The announcement is likely to have a positive impact on Pfizer's (PFE) …

Pfizer and Valneva plan to seek regulatory approval for a Lyme disease vaccine after a … High (80%)

View full analysis →

MarketWatch 80% confidence